The leadership team kicks off its appearances at the Wells Fargo 21st Annual Healthcare Conference on September 9, followed by the Morgan Stanley 24th Annual Global Healthcare Conference on September 15. The circuit concludes at the H.C. Wainwright 28th Annual Global Investment Conference on September 16. Interested investors can access live audio webcasts through the company's website, with on-demand replays available for 90 days.
In section Releases
Halozyme Executives Set for September Investor Circuit
San Diego-based biopharmaceutical firm Halozyme Therapeutics is taking its growth strategy to three major healthcare investor conferences this September. President and CEO Dr. Helen Torley and CFO Darren Snellgrove will headline the firm's engagement efforts, conducting fireside chats and one-on-one meetings to discuss the company's expanding drug delivery pipeline.
These sessions arrive as Halozyme accelerates the deployment of its ENHANZE technology, which utilizes the rHuPH20 enzyme to enable subcutaneous drug delivery. Beyond its established platform, the company is scaling its newer Hypercon and Surf Bio-derived technologies, designed to increase drug concentration and reduce injection volumes for biologics. With current partnerships spanning major firms including Roche, Pfizer, and Eli Lilly, these conferences serve as a platform for management to detail how its portfolio—ranging from ENHANZE to proprietary auto-injector products like XYOSTED—aims to reshape patient treatment adherence.
Comments (0)
No comments yet. Be the first!